Chemosensitization of hormone-refractory prostate cancer cells by curcumin to TRAIL-induced apoptosis

Journal of Experimental Therapeutics and Oncology

Volumn 5, Issue 2, 2005, Pages 81-91

  Deeb, Dorrah D ^a   Jiang, Hao ^b   Gao, Xiaohua ^a   Divine, George ^a   Dulchavsky, Scott A ^a   Gautam, Subhash C ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

Apoptosis; Caspases; Curcumin; Cytochrome c; Prostate cancer

Indexed keywords

CURCUMIN; DNA FRAGMENT; ENZYME PRECURSOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; PROCASPASE 3; PROCASPASE 8; PROCASPASE 9; PROTEIN BID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL CYCLE G1 PHASE; CHEMOSENSITIVITY; CONTROLLED STUDY; DIPLOIDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN BINDING;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASE 3; CASPASE 8; CASPASES; CELL LINE, TUMOR; CURCUMIN; DRUG SYNERGISM; G1 PHASE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; NF-KAPPA B; PROSTATIC NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 28444464762     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 50: 7-33, 2000.
2. Hanks GE. Long-term control of prostate cancer with radiation. Urol Clin North Amer 23: 605-616, 1996.
3. Garnick MB. Hormonal therapy in the management of prostate cancer: From Higgins to the present. Urology 49: 5-15, 1997.
4. Arceci RJ. Mechanism of resistance to therapy and tumor survival. Curr Opin Hematol 2: 268-274, 1995.
5. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 28: 251-265, 1996.
6. Mizutani Y, Okada Y, Fukomoto M, Bonavida B, and Yostoda O. Doxorubicin sensitizes human bladder cell carcinoma cells to Fas-mediated cytotoxicity. Cancer 79: 1180-1189, 1997.
7. Wiley SR, Schooley K, Smolak PJ, Din WS, Cuang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682, 1995.
8. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, and Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the family of the tumor necrosis factor cytokine family. J Biol Chem 271: 12687-12690, 1996.
9. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163, 1999.
10. Pollack IF, Erff M, and Ashkenazi A. Direct stimulation of apoptotic signaling by soluble Apo2L/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin Cancer Res 7: 1362-1669, 2001.
11. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:152-162, 1999.
12. Jo M Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6: 564-567, 2000.
13. Leverkus M, Neumann M, Mengling T, Rauch CT, Brocker EB, Krammer PH, et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 60: 553-559, 2000.
14. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, et al. Differential hepatotoxicity of recombinant Apo2L/TRAIL versions. Nat Med 7: 383-385, 2001.
15. Hayes RB, Ziegler RG, Gridley G, Swanson C, Greenberg RS. Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev 8: 25-34, 1999.
16. Parkin DM, Muir CS, Whelan S, Gao YT, Ferlay J, Powell J. (eds). Cancer incidence in five continents, vol VI; IARC Sci Publ No 120. Lyon, IARC, 1992.
17. Kuo SM. Dietary flavonoids and cancer prevention: Evidence and potential mechanism. Critical Rev Oncogenesis 8: 47-69, 1997.
18. Huang MT, Lysz T, Ferraro T, Abidi TF, Laskin JD, and Conney AH. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res 51: 813-819, 1991.
19. Ruby AJ, Kuttan G, Babu D, Rajasekharan KN, and Kuttan R. Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett 94: 79-83, 1995.
20. Huang MT, Newmark HL, and Frenkel K. Inhibitory effects of curcumin on tumorigenesis in mice. J Cell Biochem 27: 26-34, 1997.
21. Rao CV, Rivenson A, Simi B, Reddy BS. Chemoprevention of colon cancer by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 55: 259-266, 1995.
22. Chen HW, Huang HC. Effect of curcumin on cell cycle progression and apoptosis in vascular smooth cells. Brit J Pharmacol 124: 1029-1040, 1998.
23. Anto RJ, Mukhopadadhyay A, Denning K, and Aggarwal BB. Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xL. Carcinogenesis 23: 143-150, 2002.
24. Gautam SC, Xu YX, Pindolia KR, Janakiraman N, and Chapman RA. Nonselective inhibition of proliferation of transformed and nontransformed cells by the anticancer agent curcumin (diferuloylmethane). Biochem Pharmacol 55: 1333-1337, 1998.
25. Dorai T, Cao YC, Dorai B, Buttyan R, and Katz AE. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate 47: 293-303, 2001.
26. Deeb D, Xu YX, Jiang H, Gao X, Janakiraman N, Chapman RA, and Gautam SC. Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol Cancer Therapeutics 2: 95-103, 2003.
27. Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN. Pretreatment with paclitaxel enhances Apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res 61: 759-763, 2001.
28. Borner MM, Myers CE, Sartor O, Sei Y, Toko T, Trepel JB, Schneider E. Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res 53: 2122-2128, 1995.
29. Sherwood ER, Ford TR, Lee C, Kozlowski JM. Therapeutic efficacy of recombinant tumor necrosis factor? in an experimental model of human prostatic carcinoma. J. Biol Response Modif 9: 44-52, 1998.
30. Mizutani Y, Nakanishi H, Yoshida O, Fukushima M, Bonavida B, and Miki T. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer 38: 177-183, 2002.
31. Munshi A, McDonnell TJ, and Meyn RE. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells. Cancer Chemother Pharmacol 50: 46-52, 2002.
32. Gliniak B, Le T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 59: 6153-6158, 1999.
33. Sun X-M, MacFarlane M, Zhuang J, Wolf BB, Green DR, Cohen GM. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J Biol Chem 274: 5053-5060, 1999.
34. Ashkenazi, A, and Dixit, VM. Death receptors: Signaling and modulation. Science 281: 1305-1308, 1998.
35. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, aBcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490, 1998.
36. Weaver KD, Yeyeodu S, Cusack JC Jr, Baldwin AS Jr, Ewend MG. Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neurooncol 61: 187-96, 2003.
37. Cusack JC Jr. Overcoming antiapoptotic responses to promote chemosensitivity in metastatic colorectal cancer to the liver. Ann Surg Oncol 10: 852-62, 2003.